SCHEMBL30744730

SCHEMBL30744730

Cc1cccc(-c2ccn(C3CCCCO3)n2)n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR1 P32246 1/20 0.41
CCR8 P51685 1/20 0.41
CD274 Q9NZQ7 1/20 0.41
DRD4 P21917 3/20 0.38
HTR1A P08908 2/20 0.38
ATR Q13535 1/20 0.38
DRD2 P14416 2/20 0.37
IDH1 O75874 1/20 0.35
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
MAP3K5 Q99683 2/20 0.33
GAA P10253 1/20 0.33
METAP2 P50579 1/20 0.33
TGFBR1 P36897 4/20 0.33
TGFBR2 P37173 1/20 0.33
CYP4F2 P78329 1/20 0.32
CYP4A11 Q02928 1/20 0.32
HRH3 Q9Y5N1 1/20 0.32
TMEM97 Q5BJF2 1/20 0.32
CDK2 P24941 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20158889 0.81 CCR1 (0.48) CCR1CCR8IDH1KMT2AMETAP2
SCHEMBL13426600 0.79 CD274 (0.42) CCR1CCR8CD274IDH1KMT2A
SCHEMBL14726436 0.79 CD274 (0.40) CD274ATRIDH1MEN1KMT2A
SCHEMBL30099366 0.78 TGFBR1 (0.38) CCR1CCR8DRD4HTR1AATR
SCHEMBL30744831 0.78 TGFBR1 (0.38) CCR1CCR8DRD4HTR1AATR
SCHEMBL21315508 0.78 CCR1 (0.48) CCR1CCR8IDH1METAP2TGFBR1
SCHEMBL21325560 0.78 CCR1 (0.52) CCR1CCR8IDH1METAP2TGFBR1
SCHEMBL13425961 0.77 CD274 (0.52) CD274ATRIDH1MEN1KMT2A
SCHEMBL21325568 0.75 CCR1 (0.42) CCR1CCR8DRD4HTR1AATR
SCHEMBL28616778 0.75 CCR1 (0.42) CCR1CCR8DRD4HTR1AATR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250215017-A1 TGF-ß INHIBITOR COMPOUND AND USE THEROF MEDINNO PHARMACEUTICAL TECHNOLOGY (ZHUHAI) CO., LTD. (CN) 2025-07-03 US disclosed
US-20250179094-A1 TGF-B INHIBITOR COMPOUND AND USE THEREOF MEDINNO PHARMACEUTICAL TECHNOLOGY (ZHUHAI) CO., LTD. (CN) 2025-06-05 US disclosed
EP-4556477-A1 TGF-BETA INHIBITOR COMPOUND AND USE THEREOF Medinno Pharmaceutical Technology (Zhuhai) Co., Ltd. (CN) 2025-05-21 EP disclosed
EP-4556478-A1 TGF-BETA INHIBITOR COMPOUND AND USE THEREOF Medinno Pharmaceutical Technology (Zhuhai) Co., Ltd. (CN) 2025-05-21 EP disclosed
CN-117534686-A TGF-beta inhibitor compounds and uses thereof 河南迈英诺医药科技有限公司 2024-02-09 CN disclosed
CN-117534675-A TGF-beta inhibitor compounds and uses thereof 河南迈英诺医药科技有限公司 2024-02-09 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250179094-A1 TGF-B INHIBITOR COMPOUND AND USE THEREOF TGFB1, TGFB2, TGFBR1 CCR1 1622/4885CCR8 2548/4885CD274 1133/4885
US-20250215017-A1 TGF-ß INHIBITOR COMPOUND AND USE THEROF TGFB1, TGFB2, TGFBR2 CCR1 1656/4885CCR8 1254/4885CD274 842/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.